Results 31 to 40 of about 5,710 (181)
Evolocumab: rising momentum as novel antidyslipidemic drug [PDF]
, 2017 Increased levels of low density lipoprotein cholesterol are responsible for the major cardiovascular events. Low density lipoprotein cholesterol reduction has proved to be highly effective in reducing the risk of major cardiovascular (CV) events in ...Rimjhim Sahu, Sahu, Rimjhim, Rekha Mehani, V. K. Yadav, Yadav, V. K., Shukla, Ajay, Mehani, Rekha, Ajay Shukla +7 morecore +1 more sourceEvolocumab and clinical outcomes in patients with cardiovascular disease [PDF]
, 2017 Evolocumab and clinical outcomes in patients with cardiovascular ...Robert P Giugliano (19897608), K Kostner (11508991), C Juergens (13489768), F Charlier (19897713), R Cifkova (13338225), A Mahajan (7683152), X Li (4169308), K Korsgaard Thomsen (19898040), V Hulinsky (13588417), P Qu (19241062), Y Liu (4702669), JC Nicolau (14478252), CW Siu (14863114), H De Raedt (13445088), J Li (5099381), S Steiner (19898178), I Petrov (13416612), B Sussex (13416381), WR Ardito (19897773), G Vertes (19897845), C Cuneo (13544959), E Ferrari (13326132), PR Ferreira Rossi (19897761), J Vaclavik (19897932), D Connolly (8009855), PC Deedwania (15787181), X Chen (7409627), H Darius (13415196), VA Saavedra Gajardo (19897860), M Homza (19897998), A Hrabar (13545013), D Trendafilova-Lazarova (19897800), CH Hennekens (15787211), J Hove (19898052), F Halperin (19897821), JL Cobos (15787172), F Liu (7939259), BS Lewis (7759508), SK Wood (15787217), L Jiang (7779353), S Lehman (19897668), Z Klimsa (13588414), G Kolovou (19898220), ZA Gaciong (15787187), Z Zilahi (19898238), Julia F Kuder (19897614), MC Izar (19897782), A Saetre Lihn (19898037), H Cui (16081214), I Kellnerova (19897947), E Hernandez Triana (19897881), M Horrigan (13471495), J Yan (8134332), A Manolis (19881144), E Blumberg (19897635), H Krejcova (19880700), S Bousboulas (19898193), G Kahrmann (19898145), I Karen (19898007), H Huang (7723895), Y Cottin (13553545), J Spinar (13565923), R Simpson (7724567), J LaRosa (12040152), W Li (7678928), M Rammer (13416222), J Kuchar (19880706), E Rietzschel (19897716), L Spinarova (14479329), A Sinhal (19897671), R Pai (16350669), E Gelfand (13416300), S Pojsl (19897977), C Constance (13566007), A Scheen (7732481), H Vandekerckhove (19897698), D Bertolim Precoma (19897743), Huei Wang (10741668), MJ Charng (15787169), S Nieminen (19898073), U Kraatz (19898181), J Bergeron (19897818), LA Tavares Russo (19897725), H Pei (13404612), S Verheye (19897704), P Reichert (13588420), R Ceska (11508946), P Kazdera (19897926), MP Fish (15787160), G Schernthaner (7805687), L Soares Piegas (19897755), C Lowe (9866735), GG Rogelio (15787196), D Leeman (13416303), G Sanchez Vallejo (19897893), O Kraydashenko (13416231), H Bilianou (19898205), EB Schmidt (11845261), T Pasierski (13416210), G Ntaios (10824567), TE Abrahamsen (15787163), RL Rech (19897740), I Mackinnon (13415991), R Polasek (19897920), J Jiang (9552179), H Su (9523205), TE Strandberg (19898082), GM De Ferrari (15787178), E Perna (17000790), A Erglis (13416198), N Delarche (19898106), S Mansour (13662490), WV Brown (14548847), S Potthoff Cardenas (19897854), L Nilsson (13416243), A Pereira (7766609), P van de Borne (13346028), I Skoumas (19898208), X Yang (5161994), N Moschos (14478591), L Zhang (3204816), O Maus (19898151), B Knusel (13416174), Peter S Sever (19897620), H Bourhaial (19898142), K Sochor (19880718), I Karadi (19898265), IC Klausen (19898046), A Olsson (7773017), J Beltrame (13383303), G Thorgeirsson (13416258), E Papp (19898262), R Kryza (19880703), LA Leiter (7759523), H Kjaerulf Jensen (13416225), K Nyman (19885986), D Gossard (19897833), Z Vomacka (19898025), T Münzel (19881054), C Salamon (19898250), D Wang (4697326), L Kuchar (19897983), J Amerena (13358346), R Amoedo (19897746), B Isermann (19898163), K Toth (13416267), PA Sepulveda Varela (19897866), D Coisne (14479353), C Contzen (19898148), Y Cui (7753841), J Charvat (19897995), M Karakas (19898154), C Kurtz (13416180), J Jeppesen (19885977), JA Cuadrado (19897644), J Thoeng (14630024), JW Newcomer (15787214), G Lupkovics (14478636), A Hirayama (7804232), E Lonn (7800002), C Conejeros Kindel (19897857), Z Pozdisek (19897929), C Mariat (19898109), A Rosenthal (15969254), Y Zheng (7737209), Marc S Sabatine (9640590), A Sotomayor Herazo (19897911), H Mickley (19898049), A Singhal (7792781), WA Wan Ahmad (15787208), R de Sa Cunha (19897767), H Sinzinger (19897692), J Chen (80904), Z Zheng (9892952), Y Gu (7752434), C Berger (11060007), R Hart (7759535), N Fiserova (19897962), C Geadah (19897839), R Tarnovska-Kadreva (19897797), P Khanoyan (19880916), P Yang (7714691), Y Sun (3556880), I Podpera (19885956), C Zhou (7725038), H Rosolova (19897968), CP Pincetti Jofre (19897851), J Malecha (19885950), F Andreotti (13416276), R Chehayeb (13566004), MR Ulla (19897653), R Castellanos Bueno (19897902), P Chenu (13437147), V Velchev (19897794), T Hala (19897914), B McAdam (13416240), S Henein (19897812), M Cepelak (19897980), P Le Corvoisier (19898130), N Rost (13416315), V Adamkova (7672472), M Dunaj (19897974), H Colombo (19897641), L Nicolosi (19897647), W Van Gaal (13347693), A Mohacsi (19898256), O Dutra (14478219), A Hornyik (19898235), Y Yotov (13539073), T Piippo (19898085), M Elisaf (19898211), C Spaulding (19898136), AE Quintero Baiz (19897890), P Henry (7991954), F Mach (7746041), T Huynh (10507223), M Hanefeld (7710923), J Cha (13299429), G Range (19898100), Y Tang (7751006), G Cayla (19898112), P Garrahy (13565968), X Gao (5107775), G Gosselin (13588372), A Friart (14629991), E Nemecek (19897971), J Ferreira (13415241), S Silverman (13333860), HD Sanabria (19897662), A Begg (18374355), Z Jelinek (19898031), P Pimentel Filho (19897764), J López-Miranda (13416234), P Stawowy (19898160), MJ Tikkanen (15787202), SL Tokgozoglu (15787205), D Crowley (11552662), Y Pucheu (19898091), G Tsoukas (19897815), O Jerabek (19897923), P Motreff (19898133), J Kaik (19898061), B Herczeg (13415427), F Schiele (13416255), D Richter (7729166), G Sabe-Affaki (19897842), K Khalife (14478498), JC Moura Jorge (19897770), M Fischer (7799378), E Awtry (13416294), J Matuska (19898016), D Cross (9873755), D Angoulvant (19589947), J Kahri (19898076), A Jain (7705433), A Pande (13416312), J Wang (20900), PE Leaes (19897737), Z Yao (9147137), X Zeng (7533776), MA Moncada Corredor (19897878), BR Davis (7714799), O Ludka (19897944), SC Siu (19898232), G Reis (14478270), Z Mo (19897872), V Athyros (19898217), F Nigro (19897830), Thomas Liu (4376308), C Baigent (7783328), D Gaudet (19897827), L Tay (13409682), P Jelinek (14478414), U Hanusch (19897683), A Farshid (13416570), D Trenk (10824852), X Shen (7801967), J Ferrieres (7715159), H Nielsen (13344837), CG Rojas (19897650), Sabina A Murphy (8387337), Y Lian (11424984), L Rallidis (13416246), MP Bonaca (14880397), A Papp (19898253), P Lazov (19897803), E Peterfai (19898241), MH Vidotti (19897731), K Nagy (19881198), E Hoffer (19897707), G Kulkarni (12148725), E Kanevsky (13416162), A Hershson (14627828), P Xu (7716152), P Poirier (5539580), Stephen D Wiviott (10802797), E Catez (19897701), L Kitova (19897788), R Rouzier (19898121), M Vorpahl (19898169), L Xue (5099372), P Danias (19898223), L Mark (14478639), A Mukherjee (6734561), HR Kurtz Lisboa (19897752), K Peterka (19897950), J Krupicka (19898010), J Lalmand (19897722), G Mertzanos (19898199), T Brabec (19897959), DR Vogel (14479086), H Burianova (19897989), I Gouni-Berthold (13317861), FG Eliaschewitz (19897749), Z Li (774829), S Rahimi (19897806), AS Pandey (14479263), Terje R Pedersen (19897623), J Bronnum-Schou (19898043), A Hess (13566010), K Egstrup (19880760), T Melchior (19898055), E Kinova (19897791), R Bhargava (14478294), M Tzekova (19880628), P Salbach (19886031), CA Cure Cure (19897908), Narimon Honarpour (19897611), V Cech (19897956), M Adams (8473872), E von Hodenberg (19898184), Y Yang (6099497), JW Jukema (7672547), R Kiss (13554646), L Duchesne (19897848), JA Glenny (19897638), A Desai (7693097), P Siostrzonek (13317897), B Cariou (7757717), KYY Fan (19898229), B Merkely (11277318), P Thompson (7635290), K Huber (9215618), A Dowell (9156488), L Kritharides (13296969), D Choi (10264562), L Burgess (13412073), K Croce (13416297), DI Molina de Salazar (19897899), E St Amour (19897809), C Opitz (13748674), JL Accini Mendoza (15787166), G Gonzalez-Galvez (13416216), D Raev (13415301), P Kast (19898166), Anthony C Keech (8985387), M Amuchastegui (13539160), M Gupta (7929650), S Wagner (7753805), I Alt (19898067), Z Kosek (19898028), D Kucera (19897941), A Melidonis (19898226), G Montalescot (13555993), WK Barroso de Souza (19897776), M Hartleib (13566022), F Ruberg (13416318), AJ Lorenzatti (15787193), A Lira Pineda (13416168), D Rysava (19897986), JA Coronel Arroyo (19897887), R Somaratne (13416177), G Hetzel (19898157), S Patsilinakos (19898196), C Ho (834185), I Buysschaert (19897695), A Nagy (14478642), K Appel (16213220), J Skrobakova (19897992), D Rupka (19880661), Y Du (6951416), Z Yang (5161979), H Toplak (14629922), I Bata (13338156), A Manolova (19897785), B Ansell (13416288), P Bosiljanoff (19898172), Y Pesant (19882377), C Hengstenberg (7606652), B Paulweber (13398666), O Descamps (11508955), T Schäufele (13416219), O Ziegler (19898127), JL Cunha Borges (19897758), RG Lopez Santi (19897659), V Durlach (19898115), Y He (7724882), J Suomi (19898079), J Tomcsanyi (14478654), GA Piros (19898247), P Roberts Thomson (19897674), A Norden (13416309), B Bonnet (19898097), F Lakatos (19881183), Scott M Wasserman (19897617), S Zhao (7787582), P Hamet (13338411), R Roelandt (19897719), EC Duarte Barbosa (19897728), S Wermuth (13416228), E Zidkova (19897953), I Szakal (14479506), E VanBelle (19898139), F Pacora (19897632), R Kuchar (19898022), E Sabbah (19897824), M Viigimaa (7628531), D Murthy (9881303), R Scott (7746089), M Machkova (19897917), R Petrella (14628386), F Lanas Zanetti (19897863), L Zahn (13416291), BG Georgiev (15787190), Y Zhu (6338063), N Cox (13166919), I Schenkenberger (19881081), M Link (13416306), A Kork (19898064), G Wittert (9868331), L Elbl (19897938), J Kvasnicka (19897965), EG Hasbani (19897656), E Hajko (19898259), B Wollaert (19897710), C Ebenbichler (19897680), J Vita (19897626), D Tziakas (19881162), R Prager (16193942), K Hanlon (13416171), M De Meulemeester (13346037), A Bammert (19898103), G Kochiadakis (19898214), I Mantas (19898190), U Kassner (19898175), L Markdanner Lindgren (19898034), S Peterson (96080), C Panagoulis (19898202), D Gotchev (19880598), MV Ezhov (11508964), A Rinke (16183358), JF Kerr Saraiva (15787199), F Paillard (19898118), GA Dan (15787175), J Strand (19898070), W Huang (7725164), Z Laszlo (14479497), C Hammett (13630306), P Frana (19897935), M Savolainen (13555987), F Roubille (19898094), A Lozada (19897665), P Koleckar (19898004), I Marten (16170179), J Brotanek (19898019), D Li (660809), K Im (13416159), K Chapman (13399209), M Hissa (19897779), T Nielsen (13721665), H Dai (5161973), BA Stockins Fernandez (19897869), X Zhang (6084905), R Botero Lopez (19897884), MA Terront Lozano (19897875), ER Fernandes Manenti (19897734), I Edes (13555996), V Blaha (19898013), R Leon de la Fuente (19897629), LC Bodanese (14479152), A Baass (19897836), J Zemanek (19898001), I Valter (19898058), J Wöhrle (10824792), M Goralski (19898124), A Luger (19897686), T Anderson (7720376), J Badariene (13416186), S Vikman (19898088), S Filipová (13416204), P Andreka (19898244), A Prasan (19897677), A Sigurdsson (7634621), Z Ge (12517645), V Kothiwale (19898268), J Bergler-Klein (19897689), K Weyland (19898187), C Arana Londoño (19897896), VK Chopra (15787184), F Manzur Jattin (19897905) +499 morecore +7 more sourcesEvolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS). [PDF]
, 2019 BACKGROUND
While guidelines recommend in-hospital initiation of high-intensity statin therapy in patients with acute coronary syndromes (ACS), low-density lipoprotein cholesterol (LDL-C) target levels are frequently not attained. Evolocumab, a rapidly Deckarm, O., Mach, F., Mach, François, Crljenica, C., Mueller, Christian, Gencer, Baris, Heg, D., Crljenica, Carmela, Matter, C.M., Amini, P., Iglesias, J.F., Cook, Stéphane, Muller, O., Koskinas, K.C., Gencer, B., Windecker, S., Räber, L., Iglesias, Juan F, Heg, Dik, Muller, Olivier, Windecker, Stephan, Häner, Jonas, Mueller, C., Matter, Christian M, Pedrazzini, Giovanni, Amini, Poorya, Cook, S., Koskinas, Konstantinos C, Räber, Lorenz, Häner, J., Pedrazzini, G., Deckarm, Olga +31 morecore +3 more sourcesAtrial Fibrillation as a Possible Adverse Reaction to Evolocumab.
, 2021 Evolocumab is a recently FDA-approved proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) that reduces the risk of myocardial infarction, stroke, and coronary revascularization in individuals with established atherosclerotic cardiovascular ...Hasan, Mustajab, Hamza, Alan, Abdelmasih, Randa, Abdelmaseih, Ramy +3 morecore +1 more sourceEvolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS Study
Journal of Cardiovascular Pharmacology and Therapeutics, 2023 Purpose: We examined clinical characteristics and low-density lipoprotein cholesterol (LDL-C) lowering in patients initiating evolocumab in real-world practice in a Central and Eastern European (CEE) cohort from the pan-European HEYMANS study.Vladimír Blaha MUDr, CSc, Roman Margoczy MUDr, Ivo Petrov MD, Arman Postadzhiyan MD, PhD, FESC, FACC, Katarína Rašlová MUDr, CSc, Hana Rosolová MUDr, DrSc, Ian Bridges MSc, Nafeesa N. Dhalwani PhD, Marie Zachlederova PhD, Kausik K. Ray FESC +9 moredoaj +1 more sourceReal-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study
CJC Open, 2022 Background: The 2021 Canadian Cardiovascular Society guidelines recommend proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy in patients with atherosclerotic cardiovascular disease whose low-density lipoprotein cholesterol (LDL-C ...Milan Gupta, MD, G.B. John Mancini, MD, Rajvi J. Wani, PhD, Vineeta Ahooja, MD, Jean Bergeron, MD, MSc, Priya Manjoo, MD, A. Shekhar Pandey, MD, Maureen Reiner, MS, MA, Johnny Beltran, MD, MSc, Thiago Oliveira, MD, Erin S. Mackinnon, PhD +10 moredoaj +1 more sourceFactorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism
, 2021 Background: Monoclonal antibodies against proprotein convertase subtilisin kexin type 9 (PCSK9), such as evolocumab, lower plasma low-density lipoprotein (LDL)-cholesterol concentrations.Burrows, Sally, Barrett, P Hugh R, Watts, Gerald F, Dent, Ricardo, Chan, Dick C, Scott, Rob, Somaratne, Ransi, Wasserman, Scott M +7 morecore +1 more source
